Pyrazolo[1,5-a]pyrimidine-based inhibitors of HCV polymerase

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 22, 2009, Pages 6331-6336

  Popovici Muller, Janeta ^a   Shipps Jr , Gerald W ^a   Rosner, Kristin E ^a   Deng, Yongqi ^a   Wang, Tong ^a   Curran, Patrick J ^a   Brown, Meredith A ^a   Siddiqui, M Arshad ^a   Cooper, Alan B ^a   Duca, José ^a   Cable, Michael ^a   Girijavallabhan, Viyyoor ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

HCV polymerase inhibitors

Indexed keywords

ANTIVIRUS AGENT; CARBOXYLIC ACID DERIVATIVE; NUCLEOTIDYLTRANSFERASE INHIBITOR; PYRAZOLO[1,5 A]PYRIMIDINE DERIVATIVE; RNA POLYMERASE;

ACIDITY; ARTICLE; BIOCHEMISTRY; DRUG POTENCY; DRUG SYNTHESIS; HEPATITIS C VIRUS; HYDROPHOBICITY; NONHUMAN; STRUCTURE ACTIVITY RELATION;

DNA-DIRECTED RNA POLYMERASES; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HEPACIVIRUS; HEPATITIS C; INHIBITORY CONCENTRATION 50; MOLECULAR WEIGHT; PYRAZOLES; PYRIMIDINES; RNA REPLICASE; RNA, VIRAL; SMALL MOLECULE LIBRARIES;

HEPATITIS C VIRUS;

EID: 71049150926     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.09.087     Document Type: Article

References (35)

1. Choo Q.-L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., and Houghton M. Science 244 (1989) 359
2. Hoofnagle J.H. Hepatology 26 (1997) S15
3. World Health Organization (WHO) Hepatitis C Fact Sheet No. 164. Rev. October, 2000.
4. Cornberg M., Wedemeyer H., and Manns M.P. Curr. Gastroenterol. Rep. 4 (2000) 23
5. Beaulieu P.L., and Montse L.-B. Curr. Med. Chem. Anti-Infect. Agents 1 (2002) 163
6. Tan S.-L., Pause A., Shi Y., and Sonenberg N. Nat. Rev. Drug Disc. 1 (2002) 867
7. Adachi T., Ago H., Habuka N., Okuda K., Komatsu M., Ikeda S., and Yatsunami K. Biochim. Biophys. Acta 1601 (2002) 39
8. Huang Z., Murray M.G., and Secrist J.A. Antiviral Res. 71 (2006) 351
9. Reviews of nucleoside NS5B inhibitors:. Koch U., and Narjes F. Curr. Top. Med. Chem. 7 (2007) 1302
10. Carroll S.S., and Olsen D.B. Infect. Disorder Drug Targets 6 (2006) 17
11. Reviews of non-nucleoside NS5B inhibitors:. Beaulieu P.L. Curr. Opin. Invest. Drugs 8 (2007) 614
12. Koch U., and Narjes F. Infect. Disorder Drug Targets 6 (2006) 31
13. Dhanak D., Duffy K., Johnston V.K., Lin-Goerke J., Darcy M., Shaw A.N., Gu B., Silverman C., Gates A.T., Nonnemacher M.R., Earnshaw D.L., Casper D.J., Kaura A., Baker A., Greenwood C., Gutshall L.L., Maley D., DelVecchio A., Macarron R., Hofmann G.A., Alnoah Z., Cheng H.-Y., Chan G., Khandekar S., Keenan R.M., and Sarisky R.T. J. Biol. Chem. 277 (2002) 38322
14. Ishida T., Suzuki T., Hirashima S., Mizutani K., Yoshida A., Ando I., Ikeda S., Adachi T., and Hashimoto H. Bioorg. Med. Chem. Lett. 16 (2006) 1859
15. Koch U., Attenni B., Malancona S., Colarusso S., Conte I., Di Filippo M., Harper S., Pacini B., Giomini C., Thomas S., Incitti I., Tomei L., De Francesco R., Altamura S., Matassa V.G., and Narjes F. J. Med. Chem. 49 (2006) 1693
16. Dragovich P.S., Blazel J.K., Ellis D.A., Han Q., Kamran R., Kissinger C.R., LeBrun L.A., Li L.-S., Murphy D.E., Noble M., Patel R.A., Ruebsam F., Sergeeva M.V., Shah A.M., Showalter R.E., Tran C.V., Tsan M., Webber S.E., Kirkovsky L., and Zhou Y. Bioorg. Med. Chem. Lett. 18 (2008) 5635
17. Krueger A.C., Madigan D.L., Jiang W.W., Kati W.M., Liu D., Liu Y., Maring C.J., Masse S., McDaniel K.F., Middleton T., Mo H., Molla A., Montgomery D., Pratt J.K., Rockway T.W., Zhang R., and Kempf D.J. Bioorg. Med. Chem. Lett. 16 (2006) 3367
18. Nittoli T., Curran K., Insaf S., DiGrandi M., Orlowski M., Chopra R., Agarwal A., Howe A.Y.M., Prashad A., Floyd M.B., Johnson B., Sutherland A., Wheless K., Feld B., O'Connell J., Mansour T.S., and Bloom J. J. Med. Chem. 50 (2007) 2108
19. Habermann J., Capitò E., Ferreira M.R.R., Koch U., and Narjes F.J. Bioorg. Med. Chem. Lett. 19 (2009) 633
20. Powers J.P., Piper D.E., Li Y., Mayorga V., Anzola J., Chen J.M., Jaen J.C., Lee G., Liu J., Peterson M.G., Tonn G.R., Ye Q., Walker N.P.C., and Wang Z. J. Med. Chem. 49 (2006) 1034
21. Shipps, G. W.; Rosner K. E.; Popovici-Muller, J.; Deng, Y.; Wang, T.; Curran, P. J. U.S. 2007/7196111 (U.S. 2004/0038993).
22. Shipps, G. W.; Wang, T.; Rosner, K. E.; Curran, P. J.; Cooper, A. B.; Girijavallabhan, V. M. WO 2006/050035.
23. Hashimoto, H.; Mizutani, K.; Yoshida, A. WO 03/000254.
24. Beaulieu P.L., Bos M., Bousquet Y., Fazal G., Gauthier J., Gillard J., Goulet S., LaPlante S., Poupart M.-A., Lefebvre S., McKercher G., Pellerin C., Austel V., and Kukolj G. Bioorg. Med. Chem. Lett. 14 (2004) 119
25. Deng Y., Shipps Jr. G.W., Wang T., Popovici-Muller J., Rosner K.E., Siddiqui M.A., Duca J., and Cable M. Bioorg. Med. Chem. Lett. 19 (2009) 5363
26. 1 = OH, conversion to various substituted phenoxy analogs was done via copper promoted arylation of phenol with aryl boronic acids following a procedure by:. Evans D.A., Katz J.L., and West T.R. Tetrahedron Lett. 39 (1998) 2937 while synthesis of other aryl substituted benzyloxy analogs was accomplished either via alkylations with benzyl bromides and cesium carbonate in DMF, or Mitsunobu reactions with 'benzyl type' alcohols, triphenylphosphine and diisopropyl azodicarboxylate (DIAD).
27. 2(dppf), aryl boronates and potassium phosphate in 1,4-dioxane. This procedure was also used to explore aryl hydrophobes at C-6 as depicted in Scheme 2.
28. 50 value of a positive internal control was within standard deviation range.
29. Acid replacements on thumb domain inhibitors have been described in:. Stansfield I., Pompei M., Conte I., Ercolani C., Migliaccio G., Jairaj M., Guiliano C., Rowley M., and Narjes F. Bioorg. Med. Chem. Lett. 17 (2007) 5143
30. Herr R.J. Bioorg. Med. Chem. 10 (2002) 3379
31. The X-ray structure of an indole-based inhibitor that binds to the finger-loop region of NS5B (PDB access code: 2brk; Di Marco, S., Volpari, C., Tomei, L., Altamura, S., Harper, S., Narjes, F., Koch, U., Rowley, M., De Francesco, R., Migliaccio, G., Carfi, A., J. Biol. Chem. 2005, 280, 29765) was utilized as the frame of reference. In preparation for docking, all ligand and water molecules were deleted and hydrogen atoms were added and minimized using Macromodel as implemented in Maestro 8.5 (Schrödinger, LLC, New York, NY, 2009). Docking of 16f to NS5B was performed using Glide XP (Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard, W. T.; Banks, J. L. J. Med. Chem. 2004, 47, 1750; Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. J. Med. Chem. 2004, 47, 1739.) An inner box region (the ligand midpoint remains within this box during docking) of 10 Å and outer box region of 24 Å were used. The induced-fit docking protocol (Sherman, W.; Day, T.; Jacobson, M. P.; Friesner, R. A.; Farid, R. J. Med. Chem. 2006, 49, 534), IFD, was used to perturb the initial NS5B model in the presence of the docked ligand 16f, while allowing a flexible adaptation of the protein environment upon compound binding. All the options used during IFD were standard, as provided by the python interface in Maestro 8.5.
32. De Francesco R., and Carfí A. Adv. Drug Delivery Rev. 59 (2007) 1242
33. Beaulieu P.L. Curr. Opin. Drug Discovery Dev. 9 (2006) 618
34. Beaulieu P.L., Bös M., Bousquet Y., DeRoy P., Fazal G., Gauthier J., Gillard J., Goulet S., McKercher G., Poupart M.-A., Valois S., and Kukolj G. Bioorg. Med. Chem. Lett. 14 (2004) 967
35. Lohmann V., Körner F., Koch J.O., Herian U., Theilmann L., and Bartenschlager R. Science 285 (1999) 110